

CONCURRING STATEMENT OF COMMISSIONER ORSON SWINDLE

in *Novartis Corp., et al.*, Dkt. No. 9279

...for a stay pending appeal, review of ...  
IV of the Order. I have voted in favor of ...  
...separately to explain the differences ...  
...and those of the majority.

The Commission has granted Novartis's petition for the corrective advertising provision contained in Part IV of the Order. However, I am writing separately to explain the differences between my reasons for granting the petition and those of the majority.

When deciding whether to grant a stay, I consider: 1) the likelihood of the applicant's success on appeal; 2) whether the applicant will suffer irreparable harm if the stay is granted; 3) whether there are other factors that weigh in favor of or against the stay; and 4) whether the stay is in the public interest.

The Commission considers four factors when deciding whether to grant a stay: 1) the likelihood of the applicant's success on appeal; 2) whether the applicant will suffer irreparable harm if the stay is granted; 3) whether there are other factors that weigh in favor of or against the stay; and 4) whether the stay is in the public interest.

I will discuss each factor in turn. ...  
...the likelihood of the applicant's success on appeal. ...  
...whether the applicant will suffer irreparable harm if the stay is granted. ...  
...whether there are other factors that weigh in favor of or against the stay. ...  
...whether the stay is in the public interest. ...  
...I conclude that there is a substantial likelihood that Novartis will succeed on appeal. ...  
...I conclude that Novartis will suffer irreparable harm if the stay is not granted. ...  
...I conclude that there are no other factors that weigh in favor of or against the stay. ...  
...I conclude that the stay is in the public interest. ...

...The Commission considers four factors when deciding whether to grant a stay: 1) the likelihood of the applicant's success on appeal; 2) whether the applicant will suffer irreparable harm if the stay is granted; 3) whether there are other factors that weigh in favor of or against the stay; and 4) whether the stay is in the public interest. ...  
...I conclude that there is a substantial likelihood that Novartis will succeed on appeal. ...  
...I conclude that Novartis will suffer irreparable harm if the stay is not granted. ...  
...I conclude that there are no other factors that weigh in favor of or against the stay. ...  
...I conclude that the stay is in the public interest. ...

therefore postponed, consumers are unlikely to suffer harm because there was insufficient

the majority, I do not believe that the record shows any lingering effect, it follows that there  
be no consumer injury if the Commission grants a stay. Finally, I conclude that the stay is  
public interest because it prevents a possible injury  
injuring consumers.

My determination that all four factors to be evaluated under Rule 35  
of granting a stay is a logical outgrowth of the conclusions that I reached just  
agree that the appropriate result there is to stay the corrective advertising port

In contrast, the logical outgrowth of everything that the majority has

advertising requirement imposed with any evidence in the record.<sup>2</sup> Rather than reha  
belaboring these issues, however, I instead leave it to the Court of Appeals for the D  
Columbia Circuit to determine whether the corrective advertising provision can be s  
notwithstanding these clear discrepancies.